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Introduction Experimental
SEM Images of PLGA particles
(C-SnCt2x2H20=O.01 M)
sample 0.9% saline acetone
99mTc_PLGA Tc04- 99mTc_PLGA Tc04-
,. 65.1±0.1 34.9±O.1 64_7±O.3 35.3±O_4
2 b 87.1±0.1 12.9±O.2 88.0±O.1 12.0±0.2
3" 95.2±O.1 4.8±O.1 93.0±O.1 7.0±0.1
Table The radiochemical purity results of 99mTc-PLGA in percentages, twenty
minutes after labeling (Mean values 1: SD)
a PLGA:Sn(II)=5ml:O.005ml
b PLGA:Sn(lI~ml:O.010ml
c PLGA:Sn(1I)=5ml:O.020ml
Organ distribution data in Wistar rats for 99mTc-PLGA
The biodistributions studies of 99mTc-labeling PLGA were carried out on health white Wistar rats
(male). The animals (n=3 animals) were sacrificed thirty minuts after application of 0.1 ml of
g9mTc-labelled compound (74kBq). The radioactivity per whole organ of interest (or gram) was
measured in aNal (TI) _-detector and the percentage of radioactivity related to administrated dose
was determined.
Tissue Heart Lung Liver Spleen Kidney Stomach Intestine Blood' Bone'
%ID/organ
Imean 0.07±0.01 0.8±0.3 98.4±0.1 1.9±0.1 1.1±0.5 0.14±0.1 1.81±0.05 0.16±0.01 0.37±0.01
value±SDI
XRD patterns of al PLGA. bl PLGA with encapsulaled ascorbic acid and cl
ascorbic acid
Schematics for obtaining of the PLGAlascorbic acid nanoparticles
Results
slep1
PLGA powder is produced using physicochemical method with solvent/non-solvent
systems where obtained solutions were centrifuged. The obtained PLGA powder is non-
agglomerated, uniform and with particles sizes in the nanometer scale. The encapsulation
of ascorbic acid in the polymer matrix is performed by homogenization of water and
organic phases.
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In Ih. nanopartlcles of PLGA copoly_. dlferenl
concentration of ascorbic acid have been encapsulated and
yield In preparallon was calculaled.
Technetium-99m is still the radionuclide of choice
because of his ideal physical properties (T112=6.02h,
Ey=141keV) for many applications in nuclear
medicine. For radiopharmaceuticals preparation it
was often used like technetium pertechnetate (Tc04-),
which have to be reduced in lower oxidation state.
The results of the conditions and possibilities
investigation of poly(DL-lactide-co-glycolide) (PLGA)
labelled with 99mTc04- by stannous chloride method
were presented. The radiochemical purity,
pharmacokinetics and biodistribution of labeled
compounds were investigated.
DLPLG/ascorblc aCid (%) Yield (%)
10010 51 04
85M5 5210
70130 5641
50/50 5280
30170 53 23
The investigation of distribution and pharmacokinetics
of degraded products of PLGA is crucial for effective
prediction of host responses to PLGA in particular
applications. Thus we present a method of labeling
PLGA with 99mTc, which binds outside, leaving the
cage intact. This enables quick and convenient
investigation of pharmacological behavior and
metabolism of PLGA. The samples were characterized
by X-ray diffraction (XRD), Scanning Electron
Microscopy (SEM) and Ultraviolet Spectroscopy (UV).
For the determination of radiochemical purity of all
99mTc-labelled samples standard paper (What man
N01) and instant thin layer chromatography (ITLC-SG)
with two solvents (acetone and saline) were used.
Poly(DL-Iactide-co-glycolide) (PLGA or DLPLG) is a
strong candidate as drug carrier for a drug delivery
system because of its biocompatibility and
biodegradability. Nanoparticles act as potential carries
for several classes of drugs such as anticancer agents,
antihypertensive agents, immunomodulators,
hormones, vitamins, etc. The encapsulated ascorbic
acid within the polymeric matrix should have
significantly increased efficiency.
The degradation of the nanospheres of PLGA, PLGAlascorbic acid nanoparticles
and release rate of the vitamin were studied in vitro in PBS as degradation medium.
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Conclusion
The results ofthe examining of poly(DL-lactide-co-glycolide) (PLGA) labeled with 99mTc04- by stannous chloride method are presented. The
radiochemical study results have shown that content of free 99mTc04- in the samples is dependent on PLGA-stannous chloride ratio and is
increased with ratio. The preliminary biodistribution results for PLGA labeled with 99mTc04- by this method were: for the sample with ratio
PLGA:Sn (11)=250:1, a lot of radioactivity in liver (>98 %) may suggest these samples showed higher affinity for liver due to its hydrophobic
character or it may be an indication that in this labeling condition of samples the content of hydrolysed reduced 99mTc (99mTc02) as
radiochemical impurity was high. The next step in the research is examining the biodistributlon of 99mTc-labeled PLGA particles after the
different periods of time after their instillation into the rats, as well examining of the biodistribution of labeled PLGA particles with
encapsulated ascorbic acid.
Comparative curves for the dependence of the
absorbance maximum from the time of the
degradation for PLGA without and with ascorbic
acid
Comparative cumulative ClJ'"ves of the release of
the ascorbic acid in percentages over the period
oftime of the degradation In PBS as de,,"adation
medium
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